Chronic Kidney Disease Market Summary
As per Market Research Future analysis, the Chronic Kidney Disease Market Size was estimated at 40.53 USD Billion in 2024. The Chronic Kidney Disease industry is projected to grow from 42.87 USD Billion in 2025 to 75.22 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.78% during the forecast period 2025 - 2035
Key Market Trends & Highlights
The Chronic Kidney Disease Market is experiencing transformative growth driven by technological advancements and evolving treatment paradigms.
- Technological advancements in diagnostics are enhancing early detection and management of chronic kidney disease, particularly in North America.
- The shift towards personalized treatment approaches is gaining traction, with a focus on tailoring therapies to individual patient needs in the Asia-Pacific region.
- Integration of telehealth solutions is facilitating remote monitoring and consultations, thereby improving patient access to care across diverse demographics.
- The rising prevalence of chronic kidney disease and increased focus on preventive healthcare are key drivers propelling market growth, especially in the dialysis and blood test segments.
Market Size & Forecast
| 2024 Market Size | 40.53 (USD Billion) |
| 2035 Market Size | 75.22 (USD Billion) |
| CAGR (2025 - 2035) | 5.78% |
Major Players
Fresenius Medical Care (DE), DaVita Inc. (US), Baxter International Inc. (US), Abbott Laboratories (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (CH), Sanofi S.A. (FR), Merck & Co., Inc. (US)